MxT = Microfluidics x Therapy
Microfluidic Gene Editing for Cell Therapy Starts Right Here
We transform cancer immunotherapy, cellular engineering
and genome editing with our patented non-viral genome editing technology, Hydroporator™
Technology
Hydroporator™: Next-Generation Microfluidic cellular engineering platform accelerating the discovery, development and manufacturing of novel cell therapies
Hydroporator™ is a non-viral microfluidic platform for highly effective delivery of external cargos such as plasmid DNA, mRNA, proteins, CRISPR-Cas9 RNPs, and nanoparticles into primary cells. The Hydroporator™ technology enables high delivery efficiency, easy operation, low cost, high scalability, minimal cell perturbation (i.e., preserved cell function and viability), and cell type/cargo insensitive delivery. Hydroporator™ is free from the challenges from viral transduction, lipofection and electroporation, establishing a new avenue to accelerate cancer immunotherapy, cellular engineering and genome editing.
Fundamental advantages
Unlimited in cargo type including large sizes
Maintains viability
Highly efficient
Scalable from R&D into clinic
Effective for variety of cells
Preserved Cell Viability & Function
High Speed & Throughput Capability
Simple and Scalable
Strong Clinical Applicability
| Technologies | Efficiency | Nanoparticle delivery | Primary cell applicability | Viability | Scalability (per run) |
Cost |
|---|---|---|---|---|---|---|
| Electroporation |  (depends on cell and cargo type) |
(high Stokes drag) |
(low viability) |
(depends on cell type) |
High (104-106 cells per run) |
$10K to 100K |
| Microinjection |  (theoretically high) |
|
|
(depends on cell type) |
Low (100 cells per hour) |
$10K (injector only) |
| Viral transduction | (limited in DNA size) |
 (packaging failure) |
|
(mutagenesis concern) |
Low to High (depends on viral amount) |
High (preparation) |
| Lipofection | (depends on cell and cargo type) |
(packaging failure) |
(low efficiency for suspension cells) |
(depends on cell type) |
Low to High (depends on reagent amount) |
$1K/50 tests |
| Hydroporator™ | (>90% for human primary T cell) |
(> 300 nm) |
(immunocyte, stem cell....) |
(> 80%) |
High (106 cells per min per channel) |
~$1 (chip fabrication) |
Table reference: “Microfluidic and nanofluidic intracellular delivery”, Advanced Science (IF=16.806), 2004595 (2021)
Publications
Our Team
Aram Chung, Ph.D.
CEO & Founder
Yeonho Choi, Ph.D.
Executive Director
Soon-Tae Lee, M.D., Ph.D.
Scientific Advisor
Chin-Ha Chung, Ph.D.
Scientific Advisor
Byeongju Joo
Research & Development Team Leader
Seohyun Kim, Ph.D.
Senior Research Engineer
Hyeongtak Noh
Senior Research Engineer
Sungbin Im
Senior Research Engineer
Hojong Lee
Assistant Research Engineer
Soohyun Jeon
Research Engineer
Jiyoon Jeong
Research Engineer
Gi-Beom Kim
Management Support Team Leader
Jiyeon Han
Assistant Manager
IR & News
[액적세포천공기 국내 특허 추가 등록]
본 발명은 세포 내 물질 전달의 효율을 높이면서도 동시에 전달하여야…
엠엑스티바이오텍은 미국 현지 일정으로 1월 29일부터 2월 2일까지 4박5일간 실리콘밸리에서 '고려대 글로벌 엑셀러레이트' 프로그램에…
2023년 01월 25일 서울시 강서 마곡 산업단지에서 개최 된 (주)제넥신과 (주)툴젠 주최 초청 세미나에서…
2023년 1월 5~6일 싱가포르 국립대학교(National University of Singapore) iHteahtech Seminar와 난양공과대학교(Nanyang Technological University) 재료공학과 에서…
Partners
We are grateful to be collaborating with great partners. With their generous support, we are moving towards achieving our mission. We welcome you to join our steps towards our mission.
Contact
Contact info
#1006, Ttukseom-ro 17ga-gil 48, Seongdong-gu, Seoul, 04785, Republic of Korea
02-2157-4808 contact@mxtbiotech.com
